| Identification | Back Directory | [Name]
PI3Kδ-IN-1 | [CAS]
1911564-39-0 | [Synonyms]
ZUN64390
PI3Kδ-IN-1
PI3Kδ IN 1,PI-3Kδ-IN-1,PI3KδIN1
Benzonitrile, 2-(4-acetyl-3,3-dimethyl-2-oxo-1-piperazinyl)-4-[4-amino-5-(trifluoromethyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]- | [Molecular Formula]
C22H20F3N7O2 | [MDL Number]
MFCD31813606 | [MOL File]
1911564-39-0.mol | [Molecular Weight]
471.44 |
| Chemical Properties | Back Directory | [density ]
1.47±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 62.5 mg/mL (132.57 mM; Need ultrasonic) | [form ]
Solid | [pka]
1.10±0.30(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
PI3Kδ-IN-1 is a potent, selective, and efficacious PI3Kδ inhibitor with an IC50 of 1.7 nM. | [in vivo]
PI3Kδ-IN-1 (2, 5 mg/kg, orally b.i.d. for 42 days) shows greater than 50% suppression of paw swelling in mice. PI3Kδ-IN-1 has an EC50 of 10 nM at 24 h (ED50 of ～1.25 mg/kg) in mice[1]. | Animal Model: | Male DBA/1 mice (20?25g)[1] | | Dosage: | 0.5, 2, 5 mg/kg | | Administration: | Oral b.i.d. for 42 days, | | Result: | A dose dependent reduction of the clinical score was observed. Doses of 2 and 5 mg/kg showed greater than 50% suppression of paw swelling[1]. |
| [References]
[1] Liu Q, et al. Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders. J Med Chem. 2017 Jun 22;60(12):5193-5208. DOI:10.1021/acs.jmedchem.7b00618 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|